• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型喹诺酮和1,8-萘啶-3-甲酰胺作为具有抗癌和免疫调节活性的选择性CB2受体激动剂。

New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.

作者信息

Manera Clementina, Malfitano Anna Maria, Parkkari Teija, Lucchesi Valentina, Carpi Sara, Fogli Stefano, Bertini Simone, Laezza Chiara, Ligresti Alessia, Saccomanni Giuseppe, Savinainen Juha R, Ciaglia Elena, Pisanti Simona, Gazzerro Patrizia, Di Marzo Vincenzo, Nieri Paola, Macchia Marco, Bifulco Maurizio

机构信息

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.

Department of Medicine and Surgery, University of Salerno, Via Salvatore Allende, 84081 Baronissi, Salerno, Italy; Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 84084 Fisciano, Salerno, Italy.

出版信息

Eur J Med Chem. 2015 Jun 5;97:10-8. doi: 10.1016/j.ejmech.2015.04.034. Epub 2015 Apr 24.

DOI:10.1016/j.ejmech.2015.04.034
PMID:25935384
Abstract

Several recent studies suggest that selective CB2 receptor agonists may represent a valid pharmacological approach in the treatment of various diseases due to the absence of relevant psychoactive side effect. In this study, we synthesized and tested a series of new quinoline-2(1H)-one- and 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine derivatives characterized by a 4-methylcyclohexylamido substituent in position 3 of the heterocyclic nucleus with high CB2 receptor affinity and selectivity. Two compounds showing the best binding and selectivity profile behaved as a full agonist and a partial agonist at the CB2 receptor and induced a concentration-dependent decrease of cell viability on LNCaP, a prostatic cancer cell line expressing CB2 receptor. Moreover considering that the CB2 receptor is mainly expressed in cells and organs of the immune system, the same compounds were studied for their potential immune-modulatory and anti-inflammatory effects in activated lymphocytes isolated from healthy controls and multiple sclerosis (MS) patients.

摘要

最近的几项研究表明,由于缺乏相关的精神活性副作用,选择性CB2受体激动剂可能是治疗各种疾病的一种有效药理学方法。在本研究中,我们合成并测试了一系列新的喹啉-2(1H)-酮和4-羟基-2-氧代-1,2-二氢-1,8-萘啶衍生物,其特征在于杂环核的3位带有4-甲基环己基酰胺取代基,对CB2受体具有高亲和力和选择性。表现出最佳结合和选择性特征的两种化合物在CB2受体上分别表现为完全激动剂和部分激动剂,并在表达CB2受体的前列腺癌细胞系LNCaP上诱导细胞活力呈浓度依赖性下降。此外,鉴于CB2受体主要在免疫系统的细胞和器官中表达,我们研究了相同化合物对从健康对照和多发性硬化症(MS)患者分离的活化淋巴细胞的潜在免疫调节和抗炎作用。

相似文献

1
New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.新型喹诺酮和1,8-萘啶-3-甲酰胺作为具有抗癌和免疫调节活性的选择性CB2受体激动剂。
Eur J Med Chem. 2015 Jun 5;97:10-8. doi: 10.1016/j.ejmech.2015.04.034. Epub 2015 Apr 24.
2
Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.新型1,8-萘啶-4(1H)-酮-3-甲酰胺和喹啉-4(1H)-酮-3-甲酰胺衍生物作为CB2选择性激动剂的设计、合成及生物学评价
J Med Chem. 2006 Oct 5;49(20):5947-57. doi: 10.1021/jm0603466.
3
Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.新型 CB2 选择性大麻素受体配体的合理设计、合成及抗增殖活性研究:1,8-萘啶-2(1H)-酮骨架的探索。
Eur J Med Chem. 2012 Jun;52:284-94. doi: 10.1016/j.ejmech.2012.03.031. Epub 2012 Mar 24.
4
New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.新型1,8-萘啶和喹啉衍生物作为CB2选择性激动剂。
Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10. doi: 10.1016/j.bmcl.2007.09.089. Epub 2007 Oct 1.
5
Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists.新型1,8-萘啶-2(1H)-酮-3-甲酰胺衍生物作为高选择性大麻素-2受体激动剂的合理设计、合成及药理性质
J Med Chem. 2009 Jun 25;52(12):3644-51. doi: 10.1021/jm801563d.
6
Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis.新型 1,8-萘啶-2-酮衍生物及其类似物作为选择性 CB2 激动剂对免疫细胞的影响:在多发性硬化症中的意义。
PLoS One. 2013 May 1;8(5):e62511. doi: 10.1371/journal.pone.0062511. Print 2013.
7
Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.围绕4-氧代-1,4-二氢喹啉-3-甲酰胺类进行的药物调制,一类强效CB2选择性大麻素受体配体:对受体亲和力和功能的影响。
J Med Chem. 2007 Nov 1;50(22):5471-84. doi: 10.1021/jm070387h. Epub 2007 Oct 4.
8
1,8-Naphthyridine-3-carboxamide derivatives with anticancer and anti-inflammatory activity.具有抗癌和抗炎活性的1,8-萘啶-3-甲酰胺衍生物。
Eur J Med Chem. 2009 Aug;44(8):3356-62. doi: 10.1016/j.ejmech.2009.03.015. Epub 2009 Mar 24.
9
Anti-Proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells.新型 CB2 选择性大麻素受体激动剂在 Jurkat 白血病细胞中的抗增殖特性和促凋亡功能。
Int J Mol Sci. 2018 Jul 4;19(7):1958. doi: 10.3390/ijms19071958.
10
Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as CB receptor antagonists/inverse agonists.新型吡唑并[5,1-f][1,6]萘啶作为CB受体拮抗剂/反向激动剂的合成、分子建模及构效关系研究
Bioorg Med Chem. 2016 Nov 1;24(21):5291-5301. doi: 10.1016/j.bmc.2016.08.055. Epub 2016 Aug 29.

引用本文的文献

1
Research mapping of cannabinoids and endocannabinoid system in cancer over the past three decades: insights from bibliometric analysis.过去三十年癌症中大麻素与内源性大麻素系统的研究图谱:文献计量分析的见解
Front Pharmacol. 2025 Apr 2;16:1540619. doi: 10.3389/fphar.2025.1540619. eCollection 2025.
2
Quinoline and quinolone carboxamides: A review of anticancer activity with detailed structure-activity relationship analysis.喹啉和喹诺酮羧酰胺:抗癌活性综述及详细构效关系分析
Mol Divers. 2025 Jan 28. doi: 10.1007/s11030-024-11092-4.
3
Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists.
翻转GPCR开关:基于结构的选择性大麻素受体2反向激动剂的开发
ACS Cent Sci. 2024 Mar 11;10(5):956-968. doi: 10.1021/acscentsci.3c01461. eCollection 2024 May 22.
4
Development of a membrane-based Gi-CASE biosensor assay for profiling compounds at cannabinoid receptors.用于大麻素受体化合物分析的基于膜的Gi-CASE生物传感器检测方法的开发。
Front Pharmacol. 2023 Aug 11;14:1158091. doi: 10.3389/fphar.2023.1158091. eCollection 2023.
5
Rational drug design of CB2 receptor ligands: from 2012 to 2021.CB2受体配体的合理药物设计:2012年至2021年
RSC Adv. 2022 Dec 8;12(54):35242-35259. doi: 10.1039/d2ra05661e. eCollection 2022 Dec 6.
6
Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells.吲哚 -2- 甲酰胺类化合物对小儿脑癌细胞的合成及抗肿瘤活性评价
RSC Med Chem. 2021 Aug 23;12(11):1910-1925. doi: 10.1039/d1md00065a. eCollection 2021 Nov 17.
7
Discovery of 8-Amino-Substituted 2-Phenyl-2,7-Naphthyridinone Derivatives as New c-Kit/VEGFR-2 Kinase Inhibitors.发现 8-氨基取代的 2-苯基-2,7-萘啶酮衍生物作为新型 c-Kit/VEGFR-2 激酶抑制剂。
Molecules. 2019 Dec 5;24(24):4461. doi: 10.3390/molecules24244461.
8
Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1)-one-3-carboxamide scaffold.基于1,8-萘啶-2-(1)-酮-3-甲酰胺支架的选择性荧光大麻素2型受体配体的开发。
Medchemcomm. 2018 Oct 23;9(12):2055-2067. doi: 10.1039/c8md00448j. eCollection 2018 Dec 1.
9
Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases.大麻素化合物治疗与神经元活动相关疾病的结构-活性关系。
Molecules. 2018 Jun 25;23(7):1526. doi: 10.3390/molecules23071526.
10
Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor.PSNCBAM-1的新型类似物作为大麻素CB1受体的变构调节剂
Bioorg Med Chem. 2017 Dec 15;25(24):6427-6434. doi: 10.1016/j.bmc.2017.10.015. Epub 2017 Oct 16.